The first and only FDA - Approved Treatment for Pediatric Patients with NF1 PN| Koselugo™ (selumetinib) 10mg & 25mg capsules | for HCPs Learn about Koselugo™ (selumetinib) and its efficacy for the treatment of neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas (PN) in pediatric patients 2 years of age and older.